- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.08. | Upstream Bio, Inc. reports Q2 results | 1 | Seeking Alpha | ||
| 11.08. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| 11.08. | Upstream Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.06. | Upstream Bio präsentiert positive Phase-2-Studiendaten für Verekitug | 2 | Investing.com Deutsch | ||
| 14.06. | Upstream Bio presents positive Phase 2 trial data for verekitug | 2 | Investing.com | ||
| 14.06. | Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 | 2 | GlobeNewswire (USA) | ||
| 12.06. | JPMorgan stuft Upstream Bio wegen Umsetzungsrisiken herab | 5 | Investing.com Deutsch | ||
| 12.06. | JPMorgan downgrades Upstream Bio stock rating on execution risks | 1 | Investing.com | ||
| 10.06. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 | 224 | GlobeNewswire (Europe) | WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory... ► Artikel lesen | |
| 03.06. | H.C. Wainwright startet Coverage für Upstream Bio mit "Buy" und hohem Kursziel | 4 | Investing.com Deutsch | ||
| 03.06. | H.C. Wainwright initiates Upstream Bio stock coverage with buy rating | 1 | Investing.com | ||
| 14.05. | Mizuho lowers Upstream Bio stock price target on operating spend tweaks | 1 | Investing.com | ||
| 14.05. | Mizuho senkt Kursziel für Upstream Bio wegen angepasster Betriebsausgaben | 1 | Investing.com Deutsch | ||
| 13.05. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.04. | Upstream Bio stellt neue Daten zu Verekitug auf Fachkonferenz vor | 2 | Investing.com Deutsch | ||
| 17.04. | Upstream Bio to present verekitug data at medical conference | 1 | Investing.com | ||
| 02.04. | Truist senkt Kursziel für Upstream Bio wegen verzögertem Studienzeitplan | 4 | Investing.com Deutsch | ||
| 02.04. | Truist cuts Upstream Bio stock price target on trial timeline | 2 | Investing.com |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,798 | +0,76 % | Katalysator voraus: Valneva (ISIN: FR0004056851) setzt auf Q3-Shigella-Daten | ||
| VIVORYON THERAPEUTICS | 1,125 | -0,88 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,240 | +1,33 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| TRAWS PHARMA | 0,590 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights | Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge studyCompleted the April 2026 private... ► Artikel lesen | |
| VERASTEM | 6,280 | +0,71 % | Mizuho lowers Verastem stock price target on valuation to $13 | ||
| TRINITY BIOTECH | 9,700 | +0,31 % | Trinity Biotech expands PrePsia patent portfolio to nine patents | ||
| ZAI LAB LTD ADR | 23,000 | +1,77 % | ZAI LAB (09688): 2026 INTERIM REPORT | ||
| VOYAGER THERAPEUTICS | 2,990 | -2,03 % | H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy | ||
| TVARDI THERAPEUTICS | 1,580 | 0,00 % | Tvardi Therapeutics to Participate in Upcoming Investor Events | ||
| XBIOTECH | 1,928 | 0,00 % | XBiotech Inc.: XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis | IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment
AUSTIN, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:... ► Artikel lesen | |
| VANDA PHARMACEUTICALS | 4,710 | +3,24 % | Vanda gets EU orphan designation for psoriasis drug imsidolimab | ||
| ZEVRA THERAPEUTICS | 10,100 | +1,20 % | Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union | Company plans to request re-examination following negative CHMP opinion for arimoclomol MAA Zevra continues to support access to arimoclomol for eligible patients through its global Expanded Access... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,037 | -0,10 % | Spero Therapeutics, Inc. - 8-K, Current Report | ||
| TENAX THERAPEUTICS | 1,870 | +1,08 % | Orion Oyj: Orion's license partner Tenax Therapeutics' Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint | ORION CORPORATION STOCK EXCHANGE RELEASE - INSIDE INFORMATION 10 AUGUST 2026 at 14.05 EEST Orion's license partner Tenax Therapeutics' Phase 3 LEVEL trial of oral levosimendan in pulmonary... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,835 | +0,05 % | Vir Biotechnology climbs 9% amid post-earnings uptrend |
UPSTREAM BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 6,690 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.